Orforglipron / Osteoarthritis · Phase 3 Trial

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

ClinicalTrials.gov · September 8, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a Phase 3 RCT registration for orforglipron (GLP-1 receptor agonist) in obesity/overweight with knee osteoarthritis, currently recruiting. No efficacy or safety results are posted in this registry record, and the study is not yet complete.

What was studied

Phase 3, Interventional, Randomized, Parallel, Single masking, Treatment purpose. Osteoarthritis; age from 18 Years. Intervention: Orforglipron (GZT1); Orforglipron (GZT2). Compared with: Placebo (GZT1) — Placebo Comparator; Placebo (GZT2) — Placebo Comparator. n = 800. 88 sites across 7 countries.

Key findings

Safety

This is a registry record only; no efficacy or safety results are reported

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a registry record for a Phase 3 trial still recruiting; no results are reported, making evidence assessment impossible at this stage.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score (assessed at Baseline, Week 72)

DesignPhase 3, Interventional, Randomized, Parallel, Single masking, Treatment purpose

PopulationOsteoarthritis; age from 18 Years

Sample size800

InterventionOrforglipron (GZT1); Orforglipron (GZT2)

ComparatorPlacebo (GZT1) — Placebo Comparator; Placebo (GZT2) — Placebo Comparator

Setting88 sites across 7 countries

Reported figures

Quoted from the source exactly as published.

Estimated enrollment800

Study phasePhase 3

Primary outcome measureChange from Baseline in WOMAC Pain Subscale Score (Baseline to Week 72)

Planned study duration74 weeks

Caveats

This is a registry record only; no efficacy or safety results are reported
Study is still recruiting; completion and outcome data not yet available
Primary outcome measure is WOMAC Pain Subscale; longer-term functional or structural outcomes not specified in this record
Two independent sub-studies (J2A-MC-GZT1 and J2A-MC-GZT2) are mentioned but their distinct designs and endpoints are not detailed

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

strong

Phase 3 randomized controlled trial with placebo comparator planned

Directness

strong

Hard endpoint: WOMAC Pain Subscale in obese/overweight adults with knee OA

Consistency

insufficient

No results reported; consistency cannot be assessed from registry record

Risk of bias

insufficient

Study protocol not yet complete; allocation concealment and blinding not detailed

Sample adequacy

moderate

Estimated 800 participants across two studies; adequacy depends on final enrollment

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07153471). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 800 participants (ESTIMATED). Conditions: Osteoarthritis. Interventions: DRUG: Orforglipron; DRUG: Placebo. Primary outcome measures: Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score , Baseline, Week 72. Brief summary: The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Eli Lilly and CompanyOrforglipronNCT07153471Osteoarthritis